1. Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse May 17, 2005

2. Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse Budget Update Recent NIDA Activities & Events Recent NIDA Activities & Events Policy Issues

3. Budget Update

4. NIDA BUDGET (Thousands) Increase Over Prior Year AIDSAIDS TOTALTOTAL NonAIDSNonAIDS $677,808 $312,979 2004 Actual $990,787 +3.0% $693,282 $313,137 2005 Appropriation $1,006,419 +1.2% $707,026 $303,104 2006 P.B. $1,010,130 +0.4%

5. Policy Issues

6. Sets out broad prohibitions regarding… Outside activities Holdings Awards Sets out broad prohibitions regarding… Outside activities Holdings Awards NEW Supplemental Ethics Regulation That Affects ALL NIH Employees Current Status: Pending Response From Employees Current Status: Pending Response From Employees

7. Recent NIDA Activities & Events Recent NIDA Activities & Events

8. Collaborative Multisite Research in Addiction (COMRAD) (PA-05-067) Minority Institutions’ Drug Abuse Research Development Program (MIDARP) (PAR-05-069) Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services and Women and Sex/ Gender Differences (PAR-05-083) Inhalant Abuse: Supporting Broad-Based Research Approaches (PA-05-099) Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP) (RFA-DA-05-009) Collaborative Multisite Research in Addiction (COMRAD) (PA-05-067) Minority Institutions’ Drug Abuse Research Development Program (MIDARP) (PAR-05-069) Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services and Women and Sex/ Gender Differences (PAR-05-083) Inhalant Abuse: Supporting Broad-Based Research Approaches (PA-05-099) Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP) (RFA-DA-05-009) NIDA PAs and RFAs Just Issued

9. 13 New PAs and 4 New RFAs Foci include: Neurobiology Co-morbidity HIV/AIDS Brain Development Research Training Software/Biomedical Computing International Collaboration Foci include: Neurobiology Co-morbidity HIV/AIDS Brain Development Research Training Software/Biomedical Computing International Collaboration PAs and RFAs Recently Issued With Other NIH Components/Agencies PAs and RFAs Recently Issued With Other NIH Components/Agencies

10. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research HIV/AIDS Research Dr. Jacques Normand Will Provide an Update

11. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research Special Population/ Health Disparities Special Population/ Health Disparities Dr. Jose Szapocznik Will Report on Minority Health Disparities Workgroup Findings & Recommendations

12. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research CCTN

13. Application Receipt Date: October 14, 2004 15 Applications Received -- 4 New Applications Reviewed 13 Scored Application Receipt Date: October 14, 2004 15 Applications Received -- 4 New Applications Reviewed 13 Scored The National Drug Abuse Treatment Clinical Trials Network (RFA-DA-05-001) Issued July 7, 2004 The National Drug Abuse Treatment Clinical Trials Network (RFA-DA-05-001) Issued July 7, 2004

14. CTN Clinical Coordinating Center Contract Awarded to The EMMES Corporation CTN Clinical Coordinating Center Contract Awarded to The EMMES Corporation CTN Data and Statistics Center (DSC) Contract Awarded to Duke Clinical Research Institute (DCRI) CTN Data and Statistics Center (DSC) Contract Awarded to Duke Clinical Research Institute (DCRI)

15. Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone and methadone on liver function 10 sites, January 2006 Randomized Controlled Trial of Methylphenidate in Adolescents with ADHD and Substance Use Disorders 12 sites, Fall 2005 Methylphenidate in Maintaining Abstinence in Smokers with ADHD 6 sites, Fall 2005 Prescription Opioid Addiction Treatment Study (POATS) ~ 12 sites, Fall 2005 Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone and methadone on liver function 10 sites, January 2006 Randomized Controlled Trial of Methylphenidate in Adolescents with ADHD and Substance Use Disorders 12 sites, Fall 2005 Methylphenidate in Maintaining Abstinence in Smokers with ADHD 6 sites, Fall 2005 Prescription Opioid Addiction Treatment Study (POATS) ~ 12 sites, Fall 2005 Update on New CTN Protocols

16. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research DPMCDA

17. REPORT from the Medications Development Program Work Group 2005 National Institute on Drug Abuse National Institutes of Health U.S. Department of Health and Human Services

18. Committee Members Bankole Johnson, M.D., Ph.D. UT San Antonio Peter Kalivas, Ph.D. Med U South Carolina Herb Kleber, M.D. Columbia University George Koob, Ph.D. Scripps Research Institute Mary Jeanne Kreek, M.D. Rockefeller University Bankole Johnson, M.D., Ph.D. UT San Antonio Peter Kalivas, Ph.D. Med U South Carolina Herb Kleber, M.D. Columbia University George Koob, Ph.D. Scripps Research Institute Mary Jeanne Kreek, M.D. Rockefeller University Bertha Madras, Ph.D. Harvard Medical School Eric Nestler, M.D., Ph.D. Southwestern University Scott Reines, M.D., Ph.D. Johnson & Johnson Ray White, Ph.D. UC San Francisco Bertha Madras, Ph.D. Harvard Medical School Eric Nestler, M.D., Ph.D. Southwestern University Scott Reines, M.D., Ph.D. Johnson & Johnson Ray White, Ph.D. UC San Francisco Science Writer (Contractor) Jennifer Elcano, M.A. Science Writer (Contractor) Jennifer Elcano, M.A. NIDA Staff Denise Pintello, Ph.D. M.S.W. NIDA Staff Denise Pintello, Ph.D. M.S.W.

19. Internal Organization Create a SAB to advise on internal efficiencies & decision making Interactions with other NIDA Divisions Restructure relationships, especially with CCTN and IRP Interactions with Pharmaceutical Companies Establish NIDA as an asset to pharma for abuse liability screening and clinical trials Role of Genetics Develop a human genetic resource via collaborations between MDP and CCTN Internal Organization Create a SAB to advise on internal efficiencies & decision making Interactions with other NIDA Divisions Restructure relationships, especially with CCTN and IRP Interactions with Pharmaceutical Companies Establish NIDA as an asset to pharma for abuse liability screening and clinical trials Role of Genetics Develop a human genetic resource via collaborations between MDP and CCTN Summary of Workgroup Recommendations

20. Members Medications Development Scientific Workgroup First Meeting: Hyatt Regency Hotel Bethesda, MD March 21-22, 2005 First Meeting: Hyatt Regency Hotel Bethesda, MD March 21-22, 2005 Kenneth Davis, M.D. Lisa H. Gold, Ph.D. Suneel Gupta, Ph.D. Bankole Johnson, M.D., Ph.D. Peter Kalivas, Ph.D. Herb Kleber, M.D. Thomas R. Kosten, M.D. Susan Learned-Coughlin, Pharm.D, Ph.D. Bertha Madras, Ph.D. Eric Nestler, M.D., Ph.D. Charles P. O’Brien, M.D., Ph.D. Kenner Rice, Ph.D. Kenneth Davis, M.D. Lisa H. Gold, Ph.D. Suneel Gupta, Ph.D. Bankole Johnson, M.D., Ph.D. Peter Kalivas, Ph.D. Herb Kleber, M.D. Thomas R. Kosten, M.D. Susan Learned-Coughlin, Pharm.D, Ph.D. Bertha Madras, Ph.D. Eric Nestler, M.D., Ph.D. Charles P. O’Brien, M.D., Ph.D. Kenner Rice, Ph.D.

21. Starting Treatment with Agonist Replacement Therapies (START) Study (with CCTN) Institute-wide Workgroup with Representatives from CCTN, IRP and all Extramural Divisions Starting Treatment with Agonist Replacement Therapies (START) Study (with CCTN) Institute-wide Workgroup with Representatives from CCTN, IRP and all Extramural Divisions Interactions With Other NIDA Components

22. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research DBNBR

23. NIH IC Directors’ Roadmap Retreat April 20, 2005 NIH IC Directors’ Roadmap Retreat April 20, 2005 NIH Roadmap ACCELERATING MEDICAL DISCOVERY TO IMPROVE HEALTH Molecular Libraries

24. NIH Neuroscience Blueprint Project Team Lead IC GENSAT expansion NINDS Neurobiology of Disease Training Supplements NIMH Neuroscience Inventory NIDA Project Team Lead IC GENSAT expansion NINDS Neurobiology of Disease Training Supplements NIMH Neuroscience Inventory NIDA FY 2005 ( Tap = 0.15%) 1. Neuroimaging Training 2. Computational Neuroscience 3. Neurobiology of Disease 1. Neuroimaging Training 2. Computational Neuroscience 3. Neurobiology of Disease FY 2006 ( Tap = 0.30%) Project Team Lead IC Core Grants NINDS Neuromouse NIMH Training NIDA Project Team Lead IC Core Grants NINDS Neuromouse NIMH Training NIDA

25. Beth Babecki, NIDA Robert Baughman, NINDS Allison Chausmer, NIDA Alison Cole, NIGMS Nancy Desmond, NIMH Gayathri J Dowling, NIDA Dennis Glanzman, NIMH Lindsey Grandison, NIAAA Steven Grant, NIDA Kevin Hardwick, NIDCR Deborah Henken, NICHD Chyren Hunter, NEI Henry Khachaturian, NIBIB Teresa Levitin, NIDA Yuan Liu, NINDS Susan Molchan, NIA Beth Babecki, NIDA Robert Baughman, NINDS Allison Chausmer, NIDA Alison Cole, NIGMS Nancy Desmond, NIMH Gayathri J Dowling, NIDA Dennis Glanzman, NIMH Lindsey Grandison, NIAAA Steven Grant, NIDA Kevin Hardwick, NIDCR Deborah Henken, NICHD Chyren Hunter, NEI Henry Khachaturian, NIBIB Teresa Levitin, NIDA Yuan Liu, NINDS Susan Molchan, NIA Andrew Monjan, NIA Juanita Nelson, NIDA Nancy Pearson, NCCAM Nancy Pilotte, NIDA Suman Rao King, NIDA Charles Sharp, NIDA Carol Shreffler, NIEHS David Shurtleff, NIDA Karen Skinner, NIDA Roger Sorensen, NIAAA Daniel Sklare, NIDCD Mark Swieter, NIDA Meredith Temple-O ’ Connor, NIBIB Susan Volman, NIDA Kenneth Whang, NSF Andrew Monjan, NIA Juanita Nelson, NIDA Nancy Pearson, NCCAM Nancy Pilotte, NIDA Suman Rao King, NIDA Charles Sharp, NIDA Carol Shreffler, NIEHS David Shurtleff, NIDA Karen Skinner, NIDA Roger Sorensen, NIAAA Daniel Sklare, NIDCD Mark Swieter, NIDA Meredith Temple-O ’ Connor, NIBIB Susan Volman, NIDA Kenneth Whang, NSF Susan Weiss, NIDA, Co-Chair Laurence Stanford, NIDA, Co-Chair Neuroscience Blueprint ‘06 Training Project Team Neuroscience Blueprint ‘06 Training Project Team

26. Neuroimaging Neurobiology of Disease Computational Neuroscience Neuroimaging Neurobiology of Disease Computational Neuroscience Training Subgroups

27. Interdisciplinary Predoctoral Training in Neuroscience Imaging: Integrating First Principles and Application Purpose: To develop interdisciplinary, predoctoral training programs that integrate imaging technologies, neuroscience applications, and the underlying neurobiological principles with the aim of creating a cadre of scientists who can optimally utilize imaging technologies to address neuroscience questions Purpose: To develop interdisciplinary, predoctoral training programs that integrate imaging technologies, neuroscience applications, and the underlying neurobiological principles with the aim of creating a cadre of scientists who can optimally utilize imaging technologies to address neuroscience questions

28. Purpose: Train MD, PhD and other scientists in the multiple theories, techniques, analytic strategies and objectives of research on the neurobiology of disease Purpose: Train MD, PhD and other scientists in the multiple theories, techniques, analytic strategies and objectives of research on the neurobiology of disease Neurobiology of Disease: Training in Translational Research in Neuroscience Neurobiology of Disease: Training in Translational Research in Neuroscience

29. Computational Neuroscience: From Model to Biology and Back Again Computational Neuroscience: From Model to Biology and Back Again Purpose: Interdisciplinary training of pre- and postdoctoral fellows competent in the theories, principles and application of the physical, computer, or mathematical sciences to experimental neuroscience Purpose: Interdisciplinary training of pre- and postdoctoral fellows competent in the theories, principles and application of the physical, computer, or mathematical sciences to experimental neuroscience

30. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research DCNDBT

31. MRI Study of Normal Brain Development (N=500) Create a database of behavioral and brain MRI development data for 0-18 years Analyze structural-behavioural relationships Develop technique for dissemination of results Create a database of behavioral and brain MRI development data for 0-18 years Analyze structural-behavioural relationships Develop technique for dissemination of results The National Institute on Drug Abuse

32. Neurobiology of Behavioral Treatment: Recovery of Brain Structure and Function RFA-DA-05-006 Neurobiology of Behavioral Treatment: Recovery of Brain Structure and Function RFA-DA-05-006 22 Applications Received Consequences of Drug Abuse & Alcohol Exposure on Brain & Behavioral Development RFA-DA-05-007 Consequences of Drug Abuse & Alcohol Exposure on Brain & Behavioral Development RFA-DA-05-007 Issued with NIAAA -- 36 Applications Received HIV & Drug Abuse Interventions Among Pregnant Women in Drug Abuse Treatment RFA-DA-05-008 HIV & Drug Abuse Interventions Among Pregnant Women in Drug Abuse Treatment RFA-DA-05-008 16 Applications Received

33. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Clinical Neuroscience, Development & Behavioral Treatment Joseph Frascella, PhD Director, AIDS Research DESPR

34. Effectively Breaking the Cycle of Drugs and Crime: Research & Treatment Provide the Answers Sponsored by The Friends of NIDA March 15, 2005 Effectively Breaking the Cycle of Drugs and Crime: Research & Treatment Provide the Answers Sponsored by The Friends of NIDA March 15, 2005

35. 6 studies in the field focused on: – Reducing HIV risk behavior – Screening for mental illness – Transitioning from prison to community 2 juvenile justice studies being developed – Community re-entry and HIV risk behaviors 2 HIV studies being developed: – Men – Women 6 studies in the field focused on: – Reducing HIV risk behavior – Screening for mental illness – Transitioning from prison to community 2 juvenile justice studies being developed – Community re-entry and HIV risk behaviors 2 HIV studies being developed: – Men – Women www.cjdats.org CJ-DATS Update Criminal Justice Drug Abuse Treatment Studies 9 Research Centers 1 Coordinating Center

36. CASA Primary Care Meeting CASA Primary Care Meeting

37. Screening and Intervention for Youth in Primary Care Settings RFA-DA-04-006 Screening and Intervention for Youth in Primary Care Settings RFA-DA-04-006 Issued with SAMHSA, HRSA and AHCPR Purpose: Expand the role of primary care in addressing problem drug use—especially marijuana—among youth in the pre-dependency phase of drug abuse. 36 applications 7 awards made in September, 2004: 4 Behavioral Treatment Research 2 Health Services Research 1 Prevention Research Purpose: Expand the role of primary care in addressing problem drug use—especially marijuana—among youth in the pre-dependency phase of drug abuse. 36 applications 7 awards made in September, 2004: 4 Behavioral Treatment Research 2 Health Services Research 1 Prevention Research

38. Congressional Hearings Consequences of the Abuse of Anabolic Steroids Testimony before the Committee on Government Reform -- March 17, 2005 Fiscal Year 2006 Budget Request Testimony before the: House Subcommittee on Labor-HHS-Education Approp. -- March 9, 2005 Senate Subcommittee on Labor-HHS-Education Approp. -- April 6, 2005 Methamphetamine Abuse Testimony before the Senate Subcommittee on Labor, HHS, Education, & Related Agencies -- Committee on Appropriations -- April 21, 2005 Substance Abuse and Mental Health Research & Services Testimony before the House Subcommittee on Labor, HHS & Education Committee on Appropriations -- April 27, 2005 Consequences of the Abuse of Anabolic Steroids Testimony before the Committee on Government Reform -- March 17, 2005 Fiscal Year 2006 Budget Request Testimony before the: House Subcommittee on Labor-HHS-Education Approp. -- March 9, 2005 Senate Subcommittee on Labor-HHS-Education Approp. -- April 6, 2005 Methamphetamine Abuse Testimony before the Senate Subcommittee on Labor, HHS, Education, & Related Agencies -- Committee on Appropriations -- April 21, 2005 Substance Abuse and Mental Health Research & Services Testimony before the House Subcommittee on Labor, HHS & Education Committee on Appropriations -- April 27, 2005

39. CSAT Annual Grantees Meeting on Adolescent Treatment March 23, 2005 CSAT Annual Grantees Meeting on Adolescent Treatment March 23, 2005 2005 SAMHSA/NIDA Buprenorphine Summit April 11-12, 2005 2005 SAMHSA/NIDA Buprenorphine Summit April 11-12, 2005 Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions (CPDD) April 19-20, 2005 Methamphetamine Research Workgroup Meeting March 9-10, 2005 PRIDE 2005 – A Special Research Track from NIDA April 6-9, 2005 Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions (CPDD) April 19-20, 2005 Methamphetamine Research Workgroup Meeting March 9-10, 2005 PRIDE 2005 – A Special Research Track from NIDA April 6-9, 2005 NIDA Also Co-sponsored or Had Involvement in…

40. 9 th Annual PRISM Awards Event Beverly Hills Hotel April 28, 2005 Event will air as a one-hour TV special on FX Network September 4, 2005 at 5:00pm 9 th Annual PRISM Awards Event Beverly Hills Hotel April 28, 2005 Event will air as a one-hour TV special on FX Network September 4, 2005 at 5:00pm

41. Cannabis Dependence Treatment: Where We Are, Where We Are Going Issue Workshop Tuesday, May 24, 2005 -- 11:00 am to 12:30 pm Increases in Opioid Analgesic Abuse: Concerns and Strategies Symposium Tuesday, May 24, 2005 -- 2:00 pm to 5:00 pm New Scientific Advances in the Neurobiology of Behavior Symposium Wednesday, May 25, 2005 -- 2:00 pm to 5:00 pm Neurobiology of Compulsive Reward-Seeking Symposium Thursday, May 26, 2005 -- 2:00 pm to 5:00 pm Cannabis Dependence Treatment: Where We Are, Where We Are Going Issue Workshop Tuesday, May 24, 2005 -- 11:00 am to 12:30 pm Increases in Opioid Analgesic Abuse: Concerns and Strategies Symposium Tuesday, May 24, 2005 -- 2:00 pm to 5:00 pm New Scientific Advances in the Neurobiology of Behavior Symposium Wednesday, May 25, 2005 -- 2:00 pm to 5:00 pm Neurobiology of Compulsive Reward-Seeking Symposium Thursday, May 26, 2005 -- 2:00 pm to 5:00 pm

42. NIDA-Sponsored Events at CPDD 2005 International Forum (June 17 th - 19 th ) Review & Evaluation of NIDA Targets for Potential NIH Roadmap Library Screening Efforts NIDA Tutorials Translating Basic Research from Neural, Behavioral, & Social Sciences to Prevention Proteomics & Its Application to Drug Abuse Mice Tales: Novel Insights Into Understanding Addiction NIDA Training Mixer NIDA/CPDD Grant-writing Workshop Pharmacogenetics & Drug Abuse Research International Forum (June 17 th - 19 th ) Review & Evaluation of NIDA Targets for Potential NIH Roadmap Library Screening Efforts NIDA Tutorials Translating Basic Research from Neural, Behavioral, & Social Sciences to Prevention Proteomics & Its Application to Drug Abuse Mice Tales: Novel Insights Into Understanding Addiction NIDA Training Mixer NIDA/CPDD Grant-writing Workshop Pharmacogenetics & Drug Abuse Research June 17th June 18th June 20th June 21st June 22nd A record number of posters from CTN research will be presented at this year’s meeting A record number of posters from CTN research will be presented at this year’s meeting

44. Commissioned articles highlighting current progress in the neurobiology of feeding regulation, energy metabolism and obesity Sponsored by the Obesity Research Task Force of the National Institutes of Health Commissioned articles highlighting current progress in the neurobiology of feeding regulation, energy metabolism and obesity Sponsored by the Obesity Research Task Force of the National Institutes of Health NIDA NIDDK NIAAA NHLBI NIDA NIDDK NIAAA NHLBI